Clinical outcomes of patients who received standard and prebiotic EN
| . | Standard EN, n = 10 . | Prebiotic EN, n = 20 . | P value . |
|---|---|---|---|
| After conditioning/before BMT, n (%) | |||
| Current infection (CTCAE grade ≥2) | 0 | 0 | — |
| Additional antibiotics during conditioning (above usual prophylaxis) | 2 (20) | 4 (20) | 1.0 |
| After feeding (day +12 to day +18), n (%) | |||
| Infection since HSCT | 6 (60) | 9 (45) | .439 |
| Additional antibiotics in addition to prophylaxis since HSCT | 9 (90) | 17 (85) | 1.0 |
| Type of antibiotic, n (%) | .675 | ||
| Piptaz or meropenem included regimen | 8 (80) | 13 (65) | |
| No piptaz or meropenem | 2 (20) | 7 (35) | |
| At hospital discharge, n (%) | |||
| Current infection | 4 (40) | 8 (40) | 1.0 |
| Highest mucositis grade | 1.0 | ||
| None | 2 (20) | 3 (15) | |
| Grade 1-2 | 6 (60) | 11 (55) | |
| Grade 3-4 | 2 (20) | 6 (30) | |
| Highest grade diarrhea | .101 | ||
| None | 3 (30) | 1 (5) | |
| Grade 1-2 | 5 (50) | 16 (80) | |
| Grade 3-4 | 2 (20) | 3 (15) | |
| Duration of neutropenia from HSCT, median (Q1-Q3), d | 16 (13-19) | 15 (13-16) | .422 |
| Length of hospital stay from HSCT, median (Q1-Q3), d | 22 (17-28) | 20 (17-23) | .448 |
| Day +100 after HSCT, n (%) | |||
| Any GVHD | 6 (60) | 10 (50) | .709 |
| Gut GVHD | 0 | 5 (25) | .140 |
| Highest grade GVHD | .25 | ||
| Grade 1-2 | 6 (60) | 7 (35) | |
| Grade 3-4 | 0 | 3 (15) | |
| Disease status | .251 | ||
| Complete response | 8 (80) | 19 (95) | |
| Partial response | 1 (10) | 0 | |
| Relapsed disease | 1 (10) | 1 (5) | |
| Day-100 survival | 10 (100) | 20 (100) | 1.00 |
| . | Standard EN, n = 10 . | Prebiotic EN, n = 20 . | P value . |
|---|---|---|---|
| After conditioning/before BMT, n (%) | |||
| Current infection (CTCAE grade ≥2) | 0 | 0 | — |
| Additional antibiotics during conditioning (above usual prophylaxis) | 2 (20) | 4 (20) | 1.0 |
| After feeding (day +12 to day +18), n (%) | |||
| Infection since HSCT | 6 (60) | 9 (45) | .439 |
| Additional antibiotics in addition to prophylaxis since HSCT | 9 (90) | 17 (85) | 1.0 |
| Type of antibiotic, n (%) | .675 | ||
| Piptaz or meropenem included regimen | 8 (80) | 13 (65) | |
| No piptaz or meropenem | 2 (20) | 7 (35) | |
| At hospital discharge, n (%) | |||
| Current infection | 4 (40) | 8 (40) | 1.0 |
| Highest mucositis grade | 1.0 | ||
| None | 2 (20) | 3 (15) | |
| Grade 1-2 | 6 (60) | 11 (55) | |
| Grade 3-4 | 2 (20) | 6 (30) | |
| Highest grade diarrhea | .101 | ||
| None | 3 (30) | 1 (5) | |
| Grade 1-2 | 5 (50) | 16 (80) | |
| Grade 3-4 | 2 (20) | 3 (15) | |
| Duration of neutropenia from HSCT, median (Q1-Q3), d | 16 (13-19) | 15 (13-16) | .422 |
| Length of hospital stay from HSCT, median (Q1-Q3), d | 22 (17-28) | 20 (17-23) | .448 |
| Day +100 after HSCT, n (%) | |||
| Any GVHD | 6 (60) | 10 (50) | .709 |
| Gut GVHD | 0 | 5 (25) | .140 |
| Highest grade GVHD | .25 | ||
| Grade 1-2 | 6 (60) | 7 (35) | |
| Grade 3-4 | 0 | 3 (15) | |
| Disease status | .251 | ||
| Complete response | 8 (80) | 19 (95) | |
| Partial response | 1 (10) | 0 | |
| Relapsed disease | 1 (10) | 1 (5) | |
| Day-100 survival | 10 (100) | 20 (100) | 1.00 |
BMT, bone marrow transplantation; CTCAE, Common Terminology Criteria for Adverse Events.